|1.||Mirnajafi-Zadeh, Javad: 3 articles (02/2013 - 08/2006)|
|2.||Fathollahi, Yaghoub: 2 articles (12/2006 - 08/2006)|
|3.||Fathollahi, Y: 2 articles (11/2001 - 03/2000)|
|4.||Mirnajafi-Zadeh, J: 2 articles (11/2001 - 03/2000)|
|5.||Dar, M S: 2 articles (07/2001 - 06/2001)|
|6.||Asghari, Ali Akbar: 1 article (02/2013)|
|7.||Azarnia, Mahnaz: 1 article (02/2013)|
|8.||Javan, Mohammad: 1 article (02/2013)|
|9.||McIntosh, Victoria J: 1 article (09/2011)|
|10.||Zhan, Enbo: 1 article (09/2011)|
|1.||Status Epilepticus (Complex Partial Status Epilepticus)
01/01/1994 - "N6-Cyclohexyladenosine was also effective in terminating status epilepticus after it had progressed for 20 min. The effects of a selective A2-agonist was also tested on both stimulation models and had no anticonvulsant effects. "
01/01/1994 - "In the second study, whereas all vehicle-treated animals developed status epilepticus after constant electrical stimulation, administration of N6-cyclohexyladenosine and N6-cyclopentyladenosine prior to stimulation suppressed the development of status epilepticus. "
12/01/2006 - "Anticonvulsant effects of N6-cyclohexyladenosine microinjected into the CA1 region of the hippocampus on entorhinal cortex-kindled seizures in rats."
08/01/2006 - "In fully kindled animals, bilateral intra-amygdala N6-cyclohexyladenosine (CHA; 10-500 micromol/L, a selective A1 receptor agonist) had no effect on kindled-seizure parameters. "
03/06/2000 - "Intraperitoneal and intraamygdala N(6)-cyclohexyladenosine suppress hippocampal kindled seizures in rats."
11/01/2001 - "Results obtained showed that in kindled animals, bilateral injection of N(6)-cyclohexyladenosine (CHA), an adenosine A(1) receptor agonist, at doses of 0.1, 1 and 10 microM into the CA1 region of the hippocampus significantly decreased the afterdischarge duration and stage 5 seizure duration and increased the latency to stage 4 seizure, but there were no changes in seizure stage. "
01/01/2001 - "N6-cyclohexyladenosine and 3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid enhance the effect of antiepileptic drugs against induced seizures in mice."
|3.||Hepatocellular Carcinoma (Hepatoma)
09/01/1991 - "Increased erythropoietin secretion in human hepatoma cells by N6-cyclohexyladenosine."
01/01/1994 - "The present studies were undertaken using a cloned erythropoietin (Ep) producing hepatocellular carcinoma cell line (Hep3B) to attempt to correlate the receptor binding properties and biological activities of 5'-N-ethylcarboxamideadenosine (NECA), N6-cyclohexyladenosine (CHA) and N6-cyclopentyldenosine (CPA). "
09/01/1991 - "The present studies were undertaken to assess the direct effects of N6-cyclohexyladenosine (CHA), a stable adenosine analogue, on erythropoietin (Ep) secretion in hepatocellular carcinoma cells (Hep 3B). "
06/01/1984 - "Inhibition of the transport of adenosine, other nucleosides and hypoxanthine in novikoff rat hepatoma cells by methylxanthines, papaverine, N6-cyclohexyladenosine and N6-phenylisopropyladenosine."
06/01/1984 - "Theophylline, caffeine, isobutylmethylxanthine, papaverine, N6-cyclohexyladenosine, N6-allyl-N6-cyclohexyladenosine ( ACHA ) and N6-L-phenylisopropyladenosine (L-PIA) inhibited the transport of adenosine, uridine and hypoxanthine in Novikoff rat hepatoma cells. "
|4.||Demyelinating Diseases (Demyelinating Disease)
02/15/2013 - "Therefore, this study attempted to investigate the effect of A1 receptor agonist N6-cyclohexyladenosine (CHA), on lysolecithin (LPC) induced demyelination and remyelination in rat optic chiasm. "
02/15/2013 - "Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies."
06/29/2001 - "We have demonstrated an accentuation of cannabinoid (CP55,940)-induced motor incoordination in mice by the adenosine A(1) receptor-selective agonist N(6)-cyclohexyladenosine (CHA) (4 ng) using an intracerebellar (ICB) microinjection method. "
08/01/1998 - "The further enhancement in the ethanol-induced decrease in the striatal cyclic AMP levels by intrastriatal N6-cyclohexyladenosine, therefore, functionally correlated with the observed potentiating effect of intrastriatal N6-cyclohexyladenosine on ethanol-induced motor incoordination. "
08/01/1998 - "Forskolin also antagonized the accentuating effect of intrastriatal N6-cyclohexyladenosine on ethanol-induced motor incoordination. "
02/28/1997 - "As an extension of our previous work pertaining to brain adenosinergic modulation of ethanol-induced motor incoordination, the effect of direct intracerebellar administration of the A1-selective adenosine agonist, N6-cyclohexyladenosine (CHA) on ethanol-induced motor incoordination was evaluated. "
10/01/1994 - "The IST adenosine agonist N6-cyclohexyladenosine (CHA) markedly accentuated ethanol-induced motor incoordination in a dose-related manner, suggesting a striatal adenosinergic modulation of ethanol-induced motor incoordination. "
|2.||2-Chloroadenosine (2 Chloroadenosine)
|3.||Purinergic P1 Receptor Agonists
|4.||methyl 6,7- dimethoxy- 4- ethyl- beta- carboline- 3- carboxylate
|7.||Adenosine A1 Receptor
|9.||Ethanol (Ethyl Alcohol)